Patents Assigned to SASINAPAS CO., LTD
  • Patent number: 11866750
    Abstract: The present invention relates to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising an amino acid sequence exhibiting at least 90% sequence identity with the sequence of SEQ ID NO:1, with the proviso that the polypeptide does neither comprise the sequence according to SEQ ID NO:2, nor the sequence according to SEQ ID NO:3, nor the sequence according to SEQ ID NO:4. The present invention relates also to nucleic acids encoding an inventive polypeptide, vectors or bacteriophages comprising an inventive nucleic acid as well as host cells comprising an inventive polypeptide, nucleic acid, vector, and/or bacteriophage. Similarly, the present invention relates to compositions comprising a polypeptide, nucleic acid, vector, bacteriophage, and/or host cell according to the present invention.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: January 9, 2024
    Assignee: SASINAPAS CO., LTD.
    Inventor: Martin Griessl
  • Publication number: 20220064623
    Abstract: The present invention relates to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising an amino acid sequence exhibiting at least 90% sequence identity with the sequence of SEQ ID NO:1, with the proviso that the polypeptide does neither comprise the sequence according to SEQ ID NO:2, nor the sequence according to SEQ ID NO:3, nor the sequence according to SEQ ID NO:4. The present invention relates also to nucleic acids encoding an inventive polypeptide, vectors or bacteriophages comprising an inventive nucleic acid as well as host cells comprising an inventive polypeptide, nucleic acid, vector, and/or bacteriophage. Similarly, the present invention relates to compositions comprising a polypeptide, nucleic acid, vector, bacteriophage, and/or host cell according to the present invention.
    Type: Application
    Filed: November 18, 2021
    Publication date: March 3, 2022
    Applicant: SASINAPAS CO., LTD.
    Inventor: Martin GRIESSL
  • Patent number: 11208646
    Abstract: The present invention relates to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising an amino acid sequence exhibiting at least 90% sequence identity with the sequence of SEQ ID NO:1, with the proviso that the polypeptide does neither comprise the sequence according to SEQ ID NO:2, nor the sequence according to SEQ ID NO:3, nor the sequence according to SEQ ID NO:4. The present invention relates also to nucleic acids encoding an inventive polypeptide, vectors or bacteriophages comprising an inventive nucleic acid as well as host cells comprising an inventive polypeptide, nucleic acid, vector, and/or bacteriophage. Similarly, the present invention relates to compositions comprising a polypeptide, nucleic acid, vector, bacteriophage, and/or host cell according to the present invention.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 28, 2021
    Assignee: SASINAPAS CO., LTD.
    Inventor: Martin Griessl
  • Patent number: 11208643
    Abstract: The present invention relates in general to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising the amino acid sequence of a globular Gram-negative endolysin and the amino acid sequence of a cell wall binding domain of i) a modular Gram-negative endolysin or ii) a bacteriophage tail/baseplate protein. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, and compositions. The present inventions also relates to the use of the polypeptide, nucleic acids, vectors, bacteriophages, host cells, and compositions in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, and compositions according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: December 28, 2021
    Assignee: SASINAPAS CO., LTD.
    Inventors: Martin Griessl, Manfred Biebl
  • Patent number: 11161883
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to polypeptides comprising the sequence of a peptidoglycan hydrolase and a peptide sequence heterologous to the peptidoglycan hydrolase wherein said heterologous peptide sequence comprises a specific sequence motif which is 16, 17, 18, 19 or 20 amino acids in length. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 2, 2021
    Assignee: SASINAPAS CO., LTD
    Inventor: Martin Griessl